Coya Therapeutics (COYA) announced the launch of the ALSTARS Trial, a Phase 2, randomized, multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of COYA 302 for the treatment of ALS. Eligible study participants will be randomized to receive one of two different doses of COYA 302 or placebo in this 24-week, double-blind study. Participants who complete the initial placebo-controlled phase will be invited to enroll in an additional 24-week blinded extension to assess the long-term safety and efficacy of COYA 302. During this extension, all participants will receive COYA 302 at one of the two prespecified doses.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COYA:
- Coya Therapeutics’ COYA 303 shows anti-inflammatory effect in animal study
- Coya Therapeutics’ COYA 302 ALS trial accepted by NEALS research consortium
- Coya Therapeutics Receives $4.2M Milestone Payment
- Coya receives $4.2M milestone payment after FDA approval of IND for Coya 302
- Positive Outlook for Coya Therapeutics Amid Promising Developments and Financial Stability